Standard immunophenotyping (CD13+/CD33+/HLA-DR+) cannot differentiate TBL1XR1-RARB from PML-RARA APL, underscoring the need for routine cytogenetic/molecular profiling in pediatric AML with APL-like features. This evidence concerns the gene TBL1XR1 and acute myeloid leukemia.